Observational study / 2018
Genetically predicted cannabis use was linked to an increased risk of schizophrenia.
Researchers used 10 genetic variants associated with cannabis use in 32,330 individuals to perform a Mendelian randomization study assessing the risk of schizophrenia in 34,241 cases and 45,604 controls. Genetically predicted cannabis use was associated with an increased risk of schizophrenia (OR: 1.37; 95% CI: 1.09-1.67; P=0.007), which matched an observational meta-analysis estimate (OR: 1.43; 95% CI: 1.19-1.67). Accounting for tobacco exposure did not change the association (OR adjusted for smoking: 1.41; 95% CI: 1.09-1.83), and genetic markers showed no evidence of pleiotropic effects.
Shows an association, not proof of cause and effect.
- Study type
- Mendelian randomization study
- Who was studied
- 34,241 schizophrenia cases and 45,604 controls of predominantly European descent
- What was measured
- Risk of schizophrenia
THE PAPER
Cannabis use and risk of schizophrenia: a Mendelian randomization study.
Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, Smith DJ, Pell JP, Sattar N, Paré G, Holmes MV. Mol Psychiatry, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.